![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
| Item Type: | Review |
|---|---|
| Title: | Targeting cancer-specific mutations by T cell receptor gene therapy |
| Creators Name: | Blankenstein, T., Leisegang, M., Uckert, W. and Schreiber, H. |
| Abstract: | The ease of sequencing the cancer genome, identifying all somatic mutations and grafting mutation-specific T cell receptor (TCR) genes into T cells for adoptive transfer allow, for the first time, a truly tumor-specific and effective therapy. Mutation-specific TCR gene therapy might achieve optimal efficacy with least possible toxicity. Recent clinical data confirm the long-standing evidence from experimental cancer models that antigens encoded by the tumor-specific somatic mutations are potentially the best targets for adoptive T cell therapy. Open questions are, how many somatic mutations create suitable epitopes, whether only individual-specific or also recurrent somatic mutations qualify as suitable epitopes and how neoantigen-specific TCRs are most efficiently obtained. Tumor heterogeneity needs to be considered; therefore, it will be important to identify immunogenic driver mutations that occurred early, are essential for cancer cell survival and present in all cancer cells. |
| Keywords: | Adoptive Immunotherapy, Histocompatibility Antigens Class I, Mutation, Neoplasm Antigens, Neoplasms, Protein Binding, Recombinant Fusion Proteins, T-Cell Antigen Receptor Specificity, T-Cell Antigen Receptors, T-Lymphocyte Epitopes, T-Lymphocyte Subsets, Treatment Outcome, Animals |
| Source: | Current Opinion in Immunology |
| ISSN: | 0952-7915 |
| Publisher: | Current Biology |
| Volume: | 33 |
| Page Range: | 112-119 |
| Date: | April 2015 |
| Additional Information: | Copyright © 2015 Elsevier Ltd. All rights reserved. |
| Official Publication: | https://doi.org/10.1016/j.coi.2015.02.005 |
| External Fulltext: | View full text on PubMed Central |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
